Successful development of new approaches for the immunotherapy of cancer requires an understanding of complex, interdependent activities of early innate response elements with subsequent powerful adaptive immune responses. We are taking several novel approaches to maximize the host's ability to mount an effective antitumor response. These approaches include optimizing antigen presenting capability through the use of CD40, a TNF superfamily receptor that serves as a potent trigger for dendritic cells which provide a key interface between innate and adaptive responses. The potency of dendritic cell stimulation by agonist CD40 antibodies is enhanced when used in conjunction with IL-2 and the combination of agonist anti-CD40 plus IL-2 shows enhanced antitumor activity against metastatic kidney cancer in mice. Because CD40 is present on various hematopoietic-derived cells, endothelial cells, and some tumors themselves, we have also performed studies to definitively determine if the antitumor effects of CD40 stimulation and IL-2 were primarily mediated by CD40+ hematopoietic-derived cells. We have developed an approach where only tumor cells express functional CD40; specifically we have used models where CD40+ human tumors that respond only to anti-human CD40 were implanted in SCID mice that express only mouse CD40 and do not respond to the administration of the anti-human CD40. These two models have allowed us to show that tumor cells do respond to ligation with agonist CD40 and this response does contribute to limiting tumor growth. Another approach we have taken focuses on the fact that many successful cytokine-based therapies are totally dependent on the ability of the host to produce IFN-gamma, yet the administration of pure IFN-gamma protein has virtually no antitumor benefit in both mouse tumor models or human cancer patients. We have now developed mice lacking a functional IFN-gamma receptor (IFN-gammaR) that have allowed us to show that exposure of tumor growth and increase metastasis. Present studies are focused on how to preferentially stimulate IFN-gamma host responses while minimizing the ability of IFN-gamma to trigger immune-evading activities by the tumor itself. In addition, targeted disruption of other events in the tumor microenvironment may ultimately reveal new approaches for combining immunotherapy with other molecularly targeted strategies. In this regard, we have made expression vectors encoding the soluble forms of the VEGF receptors (VEGFRs), Flk-1 and Flt-1, linked to the constant region of human IgG1, and delivered these plasmids to Balb/c mice by highly efficient hydrodynamic injection, this strategy resulted in up to 0.1mg/ml of the appropriate gene products in mouse serum and successfully inhibited angiogenesis in VEGF-containing matrigel. Growth in vivo of a Balb/c mouse renal cancer was also blocked by the same treatment, particularly with soluble Flt-1. Overall, these types of complementary approaches seek to trigger several pathways through which the host can recognize or impair tumor growth, while also targeting the ability of tumor cells to enhance their own survival or inhibit antitumor host responses.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC009262-24
Application #
7338140
Study Section
(LEI)
Project Start
Project End
Budget Start
Budget End
Support Year
24
Fiscal Year
2006
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kudo-Saito, Chie; Wansley, Elizabeth K; Gruys, M Eilene et al. (2007) Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2. Clin Cancer Res 13:1936-46
Kummar, Shivaani; Kinders, Robert; Rubinstein, Larry et al. (2007) Compressing drug development timelines in oncology using phase '0'trials. Nat Rev Cancer 7:131-9
Peter, Marcus E; Budd, Ralph C; Desbarats, Julie et al. (2007) The CD95 receptor: apoptosis revisited. Cell 129:447-50
Weiss, Jonathan M; Subleski, Jeff J; Wigginton, Jon M et al. (2007) Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7:1705-21
Yazawa, H; Murakami, T; Li, H-M et al. (2006) Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors. Cancer Gene Ther 13:993-1001
Shorts, Lynnette; Weiss, Jonathan M; Lee, Jong-Keuk et al. (2006) Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression. J Immunol 176:6543-52
Ortaldo, John R; Winkler-Pickett, Robin T; Bere Jr, Earl W et al. (2005) In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells. J Immunol 175:693-9
Welniak, Lisbeth A; Shorts, Lynnette; Subleski, Jeff et al. (2004) Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects. Biol Blood Marrow Transplant 10:534-9
Ortaldo, John R; Young, Howard A; Winkler-Pickett, Robin T et al. (2004) Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol 172:943-53
Hussain, S Perwez; Trivers, Glennwood E; Hofseth, Lorne J et al. (2004) Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res 64:6849-53

Showing the most recent 10 out of 18 publications